Mit Ihrer Erlaubnis verwenden wir datenschutzfreundliche Analysen, um zu verstehen, welche Recherchewege funktionieren. Wir verwenden weder Werbe-Tracker noch Sitzungsaufzeichnungen. Sie können diese Auswahl in den Einstellungen ändern. Lesen Sie die Datenschutzerklärung.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
BSX — frequently asked questions
Is Boston Scientific Corporation overvalued?
In our latest published analysis dated 2026-10-22, BSX looks meaningfully undervalued. The price recorded at analysis is 44,5 USD versus our fair value of 65,9 USD; the high endpoint is presented separately as potential value of 85,8 USD. That implies roughly 48.1% upside to fair value at that date.
Our latest published report, analyzed 2026-10-22, gives BSX a fair value of 65,9 USD and a potential value of 85,8 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Boston Scientific Corporation's archetype; it is a dated research output, not a live price.
Should I buy BSX now?
Our latest published rating for BSX, analyzed 2026-10-22, is Strong Buy. Boston Scientific Corporation looks meaningfully undervalued at the analysis-date price of 44,5 USD versus fair value of 65,9 USD; potential value is 85,8 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for BSX?
The dedicated bear-case section in our report analyzed 2026-10-22 documents Boston Scientific Corporation's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is BSX's rating?
Our latest published rating for BSX, analyzed 2026-10-22, is Strong Buy, with a published moat assessment of 8/10 (Narrow). It reflects our fair value of 65,9 USD, the potential value of 85,8 USD, and the price recorded at analysis (44,5 USD).
Englische Quelle wird angezeigt, während wir übersetzen
Dieser Bericht wurde noch nicht übersetzt. Aktualisieren Sie in ein paar Minuten, sobald die Übersetzungswarteschlange aufgeholt hat.
§1 ZusammenfassungEN
30-Sekunden-AntwortStrong Buy
Preis im Verhältnis zum Wert
Kurs
$44.51
Fairer Wert
$65.94
Potenzialwert
$85.81
Stand
2026-10-21
Warum es funktionieren kann
The commercial launch of FARAPULSE Ultra and entry into the intracardiac echocardiography market in H2 2027, coupled with SEISMIQ IVL adoption and the extraction of $500M in enterprise efficiency savings, re-accelerating organic growth to 7.5% and expanding operating margins to 28.5% by FY2030.
Was unsere Einschätzung ändern würde
Deepening standalone WATCHMAN volume contraction alongside competitor PFA market entries and a 20% cut to physician reimbursement fees,,.
Boston Scientific Corporation presents a compelling investment thesis underpinned by category-leading cardiovascular franchises, robust international procedural expansion, and multi-year margin expansion initiatives. The house rating is Strong Buy. Market pricing reflects heightened concern over near-term product mix headwinds in WATCHMAN and temporary electrophysiology competitive noise, discounting a multi-year recovery powered by pulsed field ablation ecosystem expansion, SEISMIQ IVL scale, and a $500M enterprise efficiency program,.3,4
Second-quarter 2026 operational performance demonstrated resilient execution, with consolidated net sales advancing 7.5% reported and 7.0% organic to $5,442M. Adjusted EPS reached $0.86, outpacing company guidance of $0.82 to $0.84. Nevertheless, management lowered second-half expectations due to compression driven by product mix headwinds, specifically mid-teens contraction in standalone WATCHMAN volumes and imminent competitor entries in PFA,. Updated FY2026 guidance calls for 5% to 6% organic and adjusted EPS of $3.28 to $3.32,.
While consensus earnings expectations adjusted downward post-earnings—trimming FY2026 consensus EPS to $3.24 and FY2027 consensus EPS to $3.38,, —the operational inflection beginning in FY2027-FY2028 is backed by visible catalysts. Boston Scientific plans to launch FARAPULSE Ultra and enter the intracardiac echocardiography market at scale in H2 2027. Simultaneously, the pending acquisition of Penumbra strengthens peripheral thrombectomy capabilities, and the company's enterprise-wide $500M efficiency program is structured to realize over half of its savings exiting 2027.1,4
Valuation creates an attractive margin of opportunity. At $44.51, Boston Scientific trades at 13.23x forward earnings, sitting below medical technology peers such as Stryker (17.86x) and Edwards Lifesciences (26.13x). The house fair value midpoint of $65.94 reflects disciplined intrinsic cash flow modeling with operating margins expanding from 26.5% in FY2026 to 28.5% by FY2030 on an 8.0211% cost of equity, confirming our Strong Buy recommendation.2,3
Boston Scientific trades at a forward P/E of 13.23x NTM, pricing at a meaningful discount to large-cap medical device peers Stryker (17.86x) and Edwards Lifesciences (26.13x), creating a 48.1% upside gap to intrinsic fair value ($65.94),.3
Next-Generation Pulsed Field Ablation and Interventional Pipeline Catalysts
Second-generation PFA rollout with FARAPULSE Ultra and entry into intracardiac echocardiography in H2 2027 widen procedural moats, supported by coronary lithotripsy momentum from SEISMIQ IVL.4
Multi-Year Margin Expansion via Enterprise Efficiency Program
Management's $500M cost program drives structural operational leverage exiting 2027, expanding operating margins from 26.5% in FY2026 to 28.5% by FY2030 and accelerating EPS growth toward double digits.4
Hausempfehlung
Boston Scientific is positioned as a premier compounder undergoing a transitory valuation derating caused by short-term product mix shifts. With solid underlying free cash flow of $3,658M in FY2025, decisive technology upgrades arriving across EP and structural heart in 2027, and $500M in targeted operational efficiencies, the risk-reward profile strongly favors accumulation. We reiterate our Strong Buy rating.4,5
Unternehmensüberblick
Boston Scientific Corporation (NYSE: BSX) is a global developer, manufacturer, and marketer of medical devices used in interventional medical specialties. The company operates primarily across two reporting segments: Cardiovascular, which generated $13,250M in FY2025 revenue, and MedSurg, which generated $6,824M in FY2025 revenue. Offerings span electrophysiology, coronary interventions, structural heart therapies, peripheral interventions, endoscopy, urology, and neuromodulation. Effective January 1, 2027, the operational architecture will transition to three segments: Interventional Therapies, Rhythm Solutions, and MedSurg.
The business serves hospitals, healthcare clinics, and specialized medical centers internationally. In FY2025, United States operations accounted for $12,864M of net revenue, while non-US international markets delivered $7,210M (35.9% of total). Geographic diversification is led by Europe, Middle East and Africa (EMEA) generating $3,451M, Asia-Pacific (APAC) delivering $3,080M, and Latin America and Canada contributing $678M.
§2 BärenszenarioEN
The bear stress test evaluates a compound operational shock characterized by persistent structural margin degradation, delayed synergy capture, and high financial leverage. In this path, annual EPS growth decelerates to 5.0% in FY2026 and 4.5% in FY2027-FY2028, reflecting sub-3.0% organic revenue growth and adjusted operating margins stagnating below 25.0%. Total debt of $12,418M elevates interest coveragesensitivity, while prolonged gross margin compression from WATCHMAN volume declines and EP competitive incursions suppresses valuation multiples. However, Boston Scientific's diversified revenue baseline across MedSurg ($6,824M FY2025) and non-US territories ($7,210M FY2025) prevents insolvency, maintaining positive operating cash generation throughout the stress scenario.
EPS growth suppressed to 4.5% - 5.0% through FY2028.
Adjusted operating margins constrained below 25.0% from mix degradation and delayed synergies.
Wie diese These scheitern kann
Severe Product Mix Degradation and Delayed Synergy Execution
Management Q2 2026 disclosures confirmed gross margin compression from WATCHMAN and EP product mix headwinds and supply chain investments. Furthermore, Penumbra integration dilution and the delayed realization of the $500M efficiency program until late 2027, risk pulling operating margins below 25.0% instead of expanding toward 28.5%.4
FV impact
-1.5%
Operating margin 3 points lower throughout
Trigger
Within 12 months
Frühwarnsignale zur Überwachung
Die fünf Entwicklungen, die unsere Anlagethese schwächen würden.
Boston Scientific Corporation maintains a Narrow economic moat anchored by deeply integrated hospital catheter lab infrastructure, specialized physician training requirements, and comprehensive product breadth across interventional cardiology and surgical specialties. Clinical workflows in complex electrophysiology and left atrial appendage closure require institutional familiarity and extensive training, creating elevated procedural switching costs for electrophysiologists and surgical teams.
The company's commercial scale provides a formidable structural advantage in enterprise contracting. Generating $13,250M in Cardiovascular revenue and $6,824M in MedSurg revenue during FY2025, Boston Scientific pairs leading positions in PFA, coronary stenting, and structural heart with diversified MedSurg franchises in Endoscopy, Urology, and Neuromodulation. This broad portfolio shields institutional pricing and secures preferred vendor placement across health networks globally.
Regulatory moats and proprietary clinical datasets further reinforce franchise durability. Breakthrough trials such as AVANT GUARD in persistent AF and ELEVATE-PF for FARAFLEX mapping validate efficacy and safety benchmarks that competitors cannot easily replicate. While near-term competitor entries in PFA emerge in H2 2026 and H1 2027, the scheduled rollout of FARAPULSE Ultra and intracardiac echocardiography offerings in H2 2027 widens the procedural ecosystem and sustains franchise durability,.
Ökonomischer Gewinn
The business demonstrates robust economic value generation, with projected operating margins expanding from 18.0% in FY2025 to 26.5% in FY2026 and 28.5% by FY2030. This operational trajectory generates returns on capital that comfortably exceed the company's cost of capital benchmarks (WACC of 7.4785% and moderate cost of equity of 8.0211%), driving sustained economic profit expansion.2
8/ 10
Narrow
Sources of advantage
01High Switching Costs and Clinical Workflow Entrenchment — Electrophysiologists and interventional cardiologists undergo rigorous training programs and embed Boston Scientific mapping and ablation workflows into daily catheter lab operations. Procedural routines and hospital lab standardized protocols create substantial switching friction across complex structural heart and EP interventions.Wide
02Global Commercial and Distribution Infrastructure — The company commands global commercial scale across Cardiovascular ($13,250M FY2025 revenue) and MedSurg ($6,824M FY2025 revenue), enabling comprehensive enterprise procurement agreements and dedicated technical support across healthcare networks.Wide
03
Bekannte Bedrohungen für den Wettbewerbsvorteil
Bedrohung
Schweregrad
Zeitrahmen
Minderung
Competitor Pulsed Field Ablation (PFA) Introductions
medium
H2 2026 to H1 2027
Expanding the catheter ecosystem through the launch of FARAPULSE Ultra and entering the intracardiac echocardiography (ICE) market in H2 2027,.4
The highlighted cell is Fair value when every assumption sits at its base level ($65.94). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $3.8B after modeled reinvestment of $834.9M, with terminal value at 81.0% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
In the bull case, rapid clinical adoption of pulsed field ablation in international territories outpaces expectations, while FARAPULSE Ultra and ICE achieve broad commercial availability ahead of schedule in early 2027. Standalone WATCHMAN volume contraction reverses quickly as clinical education programs and 3-year CHAMPION trial data reassure physicians,. Annual diluted EPS growth reaches 14.5% to 15.0%, and operating margins expand toward top-tier peer levels.4
A quarterly operational miss caused by prolonged WATCHMAN softness or heightened PFA competition would require auditing margin degradation against the 25.0% danger threshold.
Ergebnisqualität
Reported GAAP net income of $905M ($0.61 per diluted share) for Q2 2026 reconciled to adjusted net income of $1,275M ($0.86 per diluted share). Reconciling items comprised $233M in intangible amortization ($0.14 per share), $91M in acquisition/divestiture net charges ($0.05 per share), $42M in restructuring charges ($0.02 per share), and $76M in litigation charges ($0.04 per share), offset by an $83M IEEPA tariff refund benefit (-$0.05 per share) and $70M in deferred tax adjustments ($0.05 per share). High earnings quality is supported by cash generation, where FY2025 operating cash flow of $4,534M and free cash flow of $3,658M substantially exceeded GAAP net income of $2,886M,,.3,5,6
Dynamik der Schätzungen
Consensus estimates have adjusted downward post-Q2 2026 results. Full-year FY2026 consensus diluted EPS was revised from $3.36 to $3.24,, while FY2027 diluted EPS consensus was cut from $3.71 to $3.38,. Revisions reflect management guidance indicating pressured second-half gross margins from WATCHMAN and EP product mix alongside Penumbra dilution,.1,4
Wichtige Kennzahlen vor dem Bericht
01
Kennzahl:
FARAPULSE Ultra and Intracardiac Echocardiography (ICE) Commercial Rollout
AktuellCommercial introduction planned at scale for H2 2027.
Warum es wichtig ist
Broadens the electrophysiology ecosystem and counters competing PFA catheter introductions,.4
02
Kennzahl:
WATCHMAN Standalone Volume Trajectory and Reimbursement Stabilization
AktuellRunning at mid-teens negative standalone decline in H2 2026.
Warum es wichtig ist
§8 Finanzielle Historie
Gewinn- und Verlustrechnung — letzte sechs Perioden
Cash generation is a foundational strength. In FY2025, operating cash flow reached $4,534M and free cash flow generated $3,658M after deducting capital expenditures of $876M. This represents an operating cash conversion ratio of 157% relative to FY2025 GAAP net income of $2,886M,. In the house forecast schedule, Free Cash Flow to Firm (FCFF) expands from $3,803.5M in FY2026 to $4,033.1M in FY2027, $4,465.0M in FY2028, $4,881.5M in FY2029, and $5,229.4M in FY2030. This consistent expansion provides substantial liquidity to absorb the near-term Penumbra closing while funding continuous internal R&D.3,5,6
Return on invested capital is positioned to improve as adjusted operating margins expand from 26.5% in FY2026 to 28.5% in FY2030, generating NOPAT expansion from $4,638.4M to $6,377.3M. A stable reinvestment rate of 18.0% of operating earnings preserves balance sheet capital discipline while scaling advanced catheter manufacturing.
Economic returns significantly exceed the company's weighted average cost of capital of 7.4785% and moderate cost of equity of 8.0211%, confirming strong structural economic moat value.
$500M Enterprise Efficiency Program Drives Multi-Year Operating Margin Expansion
Adjusted operating margin was 28.4% in Q2 2026 and 18.0% in FY2025. The house forecast models expanding from 26.5% in FY2026 to 28.5% in FY2030, supported by $500M in targeted efficiency savings exiting 2027.
Jüngster Umsatz20,1 Mrd. $Umsatz-CAGR +10,2 %
Betriebsmarge18,0 %10 Geschäftsjahresperioden
Jüngster freier Cashflow3,7 Mrd. $FY2025
Nettoverschuldung10,5 Mrd. $FY2025
Aufschlüsselung der Gewinn- und VerlustrechnungWie sich die Unternehmensgröße in ausgewiesenen Gewinn übersetzt.
Boston Scientific Corporation (BSX) trades at 13.2x forward earnings against a peer median of 18.1x. Its EV/EBITDA of 13.5x compares with a peer median of 15.7x. The comparison uses 4 peers: Stryker Corporation, GE HealthCare Technologies Inc., Edwards Lifesciences Corporation and STERIS plc, as of 2026-10-21 to 2026-10-22.
§10 Branche & ZyklusEN
Zyklusphase
Expansion
Medical device industry benchmarks indicate disciplined capacity deployment, with industry capex-to-revenue at 4.5% and capex-to-depreciation at 0.8. Broader industry capacity and supply chain lead times remain evidence-limited in reported data, indicating that the sector cycle view is primarily demand-led.
Bullenzyklus
In a medical technology expansion cycle, accelerating procedural volumes, rapid clinical adoption of minimally invasive catheter technologies, favorable diagnostic reimbursement, and demographic expansion compound top-line revenue growth above general GDP rates.
Bärenzyklus
In a sector downcycle, hospital capital procurement constraints, restrictive physician reimbursement codes, and aggressive pricing discounting by competing catheter vendors can compress realized product margins and stall unit volume growth.
Säkulare Trends
Trend
Auswirkung
Hinweis
Pulsed Field Ablation (PFA) Clinical Adoption
positive
The rapid transition from thermal RF/cryoablation to pulsed field ablation improves procedural safety and speed, driving expansion in treated AFib patient cohorts,.
Global Demographic Aging and Cardiovascular Disease Burden
positive
Aging global populations increase the prevalence of coronary artery disease, structural valve defects, and cardiac arrhythmias, supporting market growth rates of 7% to 8% in target procedure segments.
Healthcare Reimbursement Scrutiny and Outpatient Migration
neutral
Payer and regulatory scrutiny over hospital procedural costs, such as the 20% cut to physician reimbursement fees for WATCHMAN, requires manufacturers to substantiate clinical efficacy with long-term outcome data.
Positionierung
Boston Scientific commands leading category market shares across electrophysiology, coronary therapies, and structural heart interventions within its $13,250M Cardiovascular division, complemented by $6,824M in MedSurg. Relative to peers, BSX trades at a forward P/E of 13.23x NTM, pricing at a discount to Stryker (forward P/E 17.86x) and Edwards Lifesciences (forward P/E 26.13x), while offering superior operating margin expansion potential from 26.5% to 28.5%.3,7
§11 PositionsmanagementEN
Positionsgröße
5-7%
High conviction is supported by the Strong Buy committee rating, narrow economic moat, substantial 48.1% upside to house fair value ($65.94), low equity beta of 0.6836, and resilient cash generation across diversified business lines.2,5
Risiko
Portfolio risk is controlled by capping maximum aggregate portfolio exposure at 7.0%, enforcing strict re-underwriting triggers if adjusted operating margin falls below 25.0%, and actively monitoring currency volatility across European and Asian procedural revenue centers.
At 13.23x forward earnings, BSX trades at a significant discount to peers Stryker (17.86x) and Edwards Lifesciences (26.13x), underpinned by $3,658M in FY2025 free cash flow and expanding operating margins.3,5
Growth Compounder Perspective
Buy
Next-generation product catalysts—including FARAPULSE Ultra, ICE, and SEISMIQ IVL, —position the company to accelerate organic revenue growth to 7.5% and compound EPS at double-digit rates from FY2028.4
Risk-Sensitive / Bear Perspective
Hold
Hold pending proof that standalone WATCHMAN volume declines have arrested and that gross margin compression does not push operating margins below the 25.0% danger threshold, as competitor PFA launches could create interim pricing pressure.4
§14 Endgültige EmpfehlungEN
Aktion
Starker Kauf
Reiterating Strong Buy rating on Boston Scientific Corporation with a house Fair value of $65.94, representing 48.1% upside against $44.51 (as of 2026-10-21).3
Current market pricing reflects over-discounted pessimism regarding temporary product mix headwinds, overlooking category leadership in pulsed field ablation, secular international demand, and $500M in upcoming structural cost efficiencies,.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
In the bear case, persistent standalone volume contraction in WATCHMAN and aggressive pricing from competitor PFA launches constrain organic revenue growth below guided levels. Gross margin compression from product mix and delayed execution of the $500M efficiency program hold operating margins below 25.0%, with annual EPS growth restricted to 4.5% to 5.0%.
Prolonged WATCHMAN Defection and EP Competitive Share Loss
Standalone WATCHMAN volume contraction is running at mid-teens negative, compounded by a 20% cut to physician reimbursement fees and competitor PFA launches in H2 2026 and H1 2027,. This drives consolidated organic growth below 3.0%, breaking the 7.5% recovery profile modeled for FY2028.4
FV impact
-4.5%
Revenue and EPS growth 5 points lower for five years
Free cash flow falling below $3.0B restricts deleveraging capability against $12,418M in total debt and impairs M&A flexibility.
Aktuell:$3,658M in FY2025 (FY2026 FCFF forecast: $3,803.5M)
Alarm, wenn< $3,000M annually,
Proprietary Clinical IP and Regulatory Data Assets
— Boston Scientific established early leadership in pulsed field ablation with FARAPULSE, supported by extensive clinical validation from trials such as AVANT GUARD and ELEVATE-PF, creating proprietary clinical datasets and regulatory barriers that insulate market share.
Moderate
Physician Fee Reimbursement Cuts and Standalone WATCHMAN Softness
medium
12 to 18 months
Disseminating multi-year clinical trial evidence including 3-year CHAMPION data, educating referral communities, and advancing next-generation iterations,.4
Penumbra Acquisition Integration and Manufacturing Dilution
low
H2 2026 through FY2027
Executing an enterprise-wide $500M efficiency program targeting over half of realized savings exiting 2027.4
Discounted forecast-period cash flows (11,81 $) plus discounted terminal value (50,49 $) minus signed per current share (7,21 $) equals the 55,08 $ lens value shown above. Negative net debt is , so subtracting it raises value.
The base case models management's updated FY2026 organic revenueguidance of 5% to 6% and consensus EPS of $3.24. In FY2027, revenue advances 4.85% with EPS of $3.38 as product mix headwinds linger and Penumbra is integrated. Commencing in FY2028, revenue growth accelerates to 7.5% and operating margins reach 28.5% by FY2030 as FARAPULSE Ultra scales and $500M in efficiency savings are realized,.1,4
Reversing structural heart volume declines is required to re-expand gross margins,.
Capital deployment prioritizes operational reinvestment, strategic tuck-in technology M&A, and programmatic share repurchases. Capital expenditures totaled $876M in FY2025, supporting catheter production scale and advanced manufacturing lines, with the net reinvestment rate held constant at 18.0% of operating profit across the five-year house forecast. The company demonstrated disciplined capital return by completing a $2,000M accelerated share repurchase in Q2 2026, retiring approximately 40 million shares. Strategic capital allocation included a $1,500M investment in MiRus for a 34% equity stake and TAVR acquisition option, alongside the pending acquisition of Penumbra in H2 2026. Debt management remains sound, with total debt of $12,418M as of FY2025 ($12,624M as of October 2026) supported by strong operating cash flows.
Free cash flow stood at $3,658M in FY2025 and FCFF is projected to grow from $3,803.5M in FY2026 to $5,229.4M in FY2030 against $12,418M in total debt.
Ample liquidity facilitates smooth integration of Penumbra while sustaining tuck-in innovation investments.
Geographic Revenue Diversity Dampens US Product Line Headwinds
Non-US markets delivered $7,210M (35.9%) of FY2025 revenue, led by EMEA at $3,451M and APAC at $3,080M, with APAC growing 11.2% operationally in Q2 2026.
Strong international procedural momentum counterbalances localized US reimbursement headwinds in WATCHMAN.
